Evidence map›Paper›PMID 35623341›Full record

ArticleCancer cell2022

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.

Denise M Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Rosa I Gallagher, Pei Rong Evelyn Lee, Zelos Zhu, Mark J Magbanua, Rosalyn Sayaman, Nicholas O'Grady and 24 more

Registry-linked trialAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01042379 (I-SPY Trial), which is not on this map. Cited by 218 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
218citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01042379 phase2recruitingnot on this map

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

TypeinterventionalSponsorQuantumLeap Healthcare CollaborativeRan2010 to 2031Enrolled5,000ConditionsBreast Neoplasms, Breast Cancer, Breast Tumors, AngiosarcomaArmsStandard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab
3 · Its place in the literature

Who cites it

218 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Article
  20. Article

158 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors.

Denise M WolfDepartment of Laboratory Medicine, University of California, San Francisco, 2340 Sutter Street, San Francisco, CA 94143, USA. Electronic address: denise.wolf@ucsf.edu.
Christina YauDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: cyau@buckinstitute.org.
Julia WulfkuhleCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Lamorna Brown-SwigartDepartment of Laboratory Medicine, University of California, San Francisco, 2340 Sutter Street, San Francisco, CA 94143, USA.
Rosa I GallagherCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Pei Rong Evelyn LeeDepartment of Laboratory Medicine, University of California, San Francisco, 2340 Sutter Street, San Francisco, CA 94143, USA.
Zelos ZhuDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Mark J MagbanuaDepartment of Laboratory Medicine, University of California, San Francisco, 2340 Sutter Street, San Francisco, CA 94143, USA.
Rosalyn SayamanDepartment of Laboratory Medicine, University of California, San Francisco, 2340 Sutter Street, San Francisco, CA 94143, USA.
Nicholas O'GradyDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Amrita BasuDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Amy DelsonBreast Science Advocacy Core, University of California, San Francisco, San Francisco, CA 94143, USA.
Jean Philippe CoppéDepartment of Laboratory Medicine, University of California, San Francisco, 2340 Sutter Street, San Francisco, CA 94143, USA.
Ruixiao LuQuantum Leap Healthcare Collaborative, San Francisco, CA 94118, USA.
Jerome BraunQuantum Leap Healthcare Collaborative, San Francisco, CA 94118, USA.
I-SPY2 Investigators
Smita M AsareQuantum Leap Healthcare Collaborative, San Francisco, CA 94118, USA.
Laura SitDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Jeffrey B MatthewsDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Jane PerlmutterGemini Group, Ann Arbor, MI 48107, USA.
Nola HyltonDepartment of Radiology, University of California, San Francisco, San Francisco, CA 94143, USA.
Minetta C LiuDepartment of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Paula PohlmannMedStar Georgetown University Hospital, Georgetown University, Washington, DC 20057, USA.
W Fraser SymmansDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hope S RugoDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, CA 94158, USA.
Claudine IsaacsLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA.
Angela M DeMichelePerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Douglas YeeDepartment of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
Donald A BerryBerry Consultants, LLC, Austin, TX 78746, USA.
Lajos PusztaiYale School of Medicine, Yale University, New Haven, CT 06510, USA.
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Gillian L HirstDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Laura J EssermanDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Laura J van 't VeerDepartment of Laboratory Medicine, University of California, San Francisco, 2340 Sutter Street, San Francisco, CA 94143, USA. Electronic address: laura.vantveer@ucsf.edu.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Leigh Clarke · 1999 to 2026
$209.7M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer OutcomesP01CA210961 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nola M. Hylton-Watson · 2017 to 2026
$22.9M
Training SubprojectU54HG007990 · NHGRI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI HAUSSLER, DAVID H, PATTERSON, DAVID · 2014 to 2018
$14.8M
Using Networks to Seed Hierarchical Whole-cell Models of CancerU54CA209891 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI IDEKER, TREY · 2017 to 2021
$10.9M
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancerR01CA255442 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LI, WEN, MAGBANUA, MARK JESUS · 2021 to 2025
$3.3M
Quantitative Imaging for Assessing Breast Cancer Response to TreatmentU01CA225427 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HYLTON-WATSON, NOLA M. · 2018 to 2022
$3.2M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P01 CA210961NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA255442NCI NIH HHS U01 CA225427NCI NIH HHS U54 CA209891NHGRI NIH HHS U54 HG007990
6 · The paper itself

Abstract

Using pre-treatment gene expression, protein/phosphoprotein, and clinical data from the I-SPY2 neoadjuvant platform trial (NCT01042379), we create alternative breast cancer subtypes incorporating tumor biology beyond clinical hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) status to better predict drug responses. We assess the predictive performance of mechanism-of-action biomarkers from ∼990 patients treated with 10 regimens targeting diverse biology. We explore >11 subtyping schemas and identify treatment-subtype pairs maximizing the pathologic complete response (pCR) rate over the population. The best performing schemas incorporate Immune, DNA repair, and HER2/Luminal phenotypes. Subsequent treatment allocation increases the overall pCR rate to 63% from 51% using HR/HER2-based treatment selection. pCR gains from reclassification and improved patient selection are highest in HR

Indexed as

Breast NeoplasmsAdaptive Clinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansNeoadjuvant TherapyReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesteronebreast cancerclinical trialDNA repairImmuneimmunotherapyLuminalmultiple armsplatinumresponse predictionsubtyping

Identifiers

PMID35623341
PMCPMC9426306

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.